文献速递淋巴瘤

血管免疫母细胞性T细胞淋巴瘤:基于游离DNA分析的新复发突变与预后生物标志物

Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling.
PubMed 文献 · Br J Haematol · 2023-08-30

本研究采用含46个基因的定制panel,对来自三个临床中心的64例中国血管免疫母细胞性T细胞淋巴瘤(AITL)患者治疗前游离DNA(cfDNA)及配对肿瘤组织进行测序,34对样本评估一致性。cfDNA与组织测序结果一致性良好,鉴定出KDM5A、STAT1、FANCM、ERBB4、PIK3R5和NSD1为新复发突变;FANCM突变或RHOA、KDM5A与FAT1组合突变与不良预后相关。

要点

  • cfDNA与配对肿瘤组织测序结果一致性良好,支持cfDNA作为AITL液体活检工具。
  • 鉴定出KDM5A、STAT1、FANCM、ERBB4、PIK3R5和NSD1为新复发突变。
  • FANCM突变或RHOA、KDM5A与FAT1组合突变与不良预后相关。

核心结论

  • cfDNA可作为AITL的液体活检工具,并揭示可用于患者分层和指导治疗选择的新分子决定因素。

研究设计与样本

  • 研究采用含46个基因的定制panel,对来自三个临床中心的64例中国AITL患者治疗前cfDNA及配对肿瘤组织进行测序,其中34对样本用于评估cfDNA与肿瘤组织突变的一致性。

主要发现

  • cfDNA样本与配对组织样本测序结果一致性良好。
  • KDM5A、STAT1、FANCM、ERBB4、PIK3R5和NSD1被鉴定为新复发突变。
  • FANCM突变或RHOA、KDM5A与FAT1的组合突变与不良预后相关。
  • 功能分析显示RHOAG17可能作为PD-1阻断反应的预测生物标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Molecular and clinical stratification of patients with angioimmunoblastic T-cell lymphoma (AITL) is unsatisfactory, which hinders the development of personalized therapies. This study aimed to identify molecular biomarkers for AITL based on peripheral cell-free DNA (cfDNA) that could be used to predict prognosis and guide treatment non-invasively. A customized panel containing 46 genes was used to study pretreatment cfDNA and paired tumour tissues in 64 Chinese AITL patients from three clinical centres, and gene mutations in cfDNA and tumour tissue were assessed for concordance (34 paired samples). Then, the association of gene mutations and prognosis was analysed, and a functional enrichment analysis was performed. The sequencing results showed good consistency between cfDNA samples and paired tissue samples. KDM5A, STAT1, FANCM, ERBB4, PIK3R5 and NSD1 were identified as novel recurrent mutations. Mutations in FANCM or combinations of RHOA, KDM5A and FAT1 were associated with poor prognosis. Additionally, functional analysis revealed that RHOAG17 might serve as a predictive biomarker of PD-1 blockade respondence. Our findings confirmed the role of cfDNA as a liquid biopsy in AITL, and revealed novel molecular determinants that can stratify patients and guide treatment options.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang C, Mou B, Xu J, et al. Angioimmunoblastic T-cell lymphoma: Novel recurrent mutations and prognostic biomarkers by cell-free DNA profiling. Br J Haematol. 2023. PMID: 37646306. doi:10.1111/bjh.19089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。